196 related articles for article (PubMed ID: 36765559)
1. Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response.
Lejeune M; Reverté L; Sauras E; Gallardo N; Bosch R; Roso A; Petit A; Peg V; Riu F; García-Fontgivell J; Ibáñez J; Relea F; Vieites B; Bor C; de la Cruz-Merino L; Arenas M; Rodriguez V; Galera J; Korzynska A; Belhomme P; Plancoulaine B; Álvaro T; López C
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765559
[TBL] [Abstract][Full Text] [Related]
2. Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
Lejeune M; Reverté L; Gallardo N; Sauras E; Bosch R; Mata D; Roso A; Petit A; Peg V; Riu F; García-Fontgivell J; Relea F; Vieites B; de la Cruz-Merino L; Arenas M; Rodriguez V; Galera J; Korzynska A; Plancoulaine B; Álvaro T; López C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511057
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
4. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
6. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
da Silva JL; de Albuquerque LZ; Rodrigues FR; de Mesquita GG; Fernandes PV; Thuler LCS; de Melo AC
Front Oncol; 2021; 11():636716. PubMed ID: 34858800
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
11. Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Ilie SM; Briot N; Constatin G; Ilie A; Beltjens F; Ladoire S; Desmoulins I; Hennequin A; Bertaut A; Coutant C; Causeret S; Ghozali N; Coudert B; Arnould L
Front Oncol; 2023; 13():1309890. PubMed ID: 38273853
[TBL] [Abstract][Full Text] [Related]
12. Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.
Giacchetti S; Faucheux L; Gardair C; Cuvier C; de Roquancourt A; Campedel L; Groheux D; de Bazelaire C; Lehmann-Che J; Miquel C; Cahen Doidy L; Amellou M; Madelaine I; Reyal F; Someil L; Hocini H; Hennequin C; Teixeira L; Espié M; Chevret S; Soumelis V; Hamy AS
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267639
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
[TBL] [Abstract][Full Text] [Related]
14. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
Pang J; Zhou H; Dong X; Wang S; Xiao Z
Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
[TBL] [Abstract][Full Text] [Related]
16. Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy.
Wang G; Yao Y; Huang H; Zhou J; Ni C
Front Oncol; 2023; 13():1131259. PubMed ID: 37284197
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.
Lin Y; Lin E; Li Y; Chen X; Chen M; Huang J; Guo W; Chen L; Wu L; Zhang X; Zhang W; Jin X; Zhang J; Fu F; Wang C
Pathol Oncol Res; 2022; 28():1610559. PubMed ID: 36405394
[No Abstract] [Full Text] [Related]
18. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
[TBL] [Abstract][Full Text] [Related]
20. Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy.
Wang Y; Zong B; Yu Y; Wang Y; Tang Z; Chen R; Huang M; Liu S
Front Oncol; 2021; 11():668610. PubMed ID: 34235079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
